<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="370067">
  <stage>Registered</stage>
  <submitdate>7/02/2016</submitdate>
  <approvaldate>17/08/2016</approvaldate>
  <actrnumber>ACTRN12616001119482</actrnumber>
  <trial_identification>
    <studytitle>Characterization of selenium and glutathione status in critically ill children.</studytitle>
    <scientifictitle>Characterization of selenium and glutathione status in critically ill children.</scientifictitle>
    <utrn>U1111-1179-2507</utrn>
    <trialacronym />
    <secondaryid>Nil known</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Critically ill</healthcondition>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Other inflammatory or immune system disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Serum selenium concentration and glutathione status will be measured at admission and at day 5 in critically ill children and newborns.</interventions>
    <comparator>Healthy children set up for elective surgery will be sampled for serum Selenium concentration and glutathione status after induction of anesthesia.</comparator>
    <control>Active</control>
    <interventioncode>Not applicable</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Characterize serum Selenium concentration at admission to Intensive care and at day five.</outcome>
      <timepoint>Day 5 compared to Admission (Day 1).</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Investigate if Serum Glutathione status at Admission and day five is linked to serum Selenium concentration.</outcome>
      <timepoint>Day 5 compared to admission (Day 1).</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Organ failure assessment according to PELOD Score at Admission and day five, and correlation to serum Selenium concentration.</outcome>
      <timepoint>Day 5 compared to admission (Day 1).</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>&lt;18 years of age; BW &gt;1000 grams; expected time in PICU &gt;24 hours
</inclusivecriteria>
    <inclusiveminage />
    <inclusiveminagetype>No limit</inclusiveminagetype>
    <inclusivemaxage>18</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>BW &lt;1000 grams; Age &gt;= 18 years; Expected time in PICU &lt;24 hours; moribund patient</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods>T test, Mann-Withney U test, Wilcoxon, Kruskal-Wallis, one-way ANOVA, and Tukeys post hoc test.
At the time the study was planned there was no available data regarding the variation in selenium concentration in critically ill children. In addition, in Sweden there is no information of the selenium concentration in healthy children. Sixty healthy patients were used as controls/reference.. This information was crucial for the study and also important to know since the soil in Sweden has a low content of selenium and to evaluate if the selenium concentration was age dependent. 
The main reason for choosing 100 critically ill patients was to generate a sufficient number of patients at day 5. In Scandinavian PICUs approximately 30 % of the patients have a PICU-stay &gt; 5 days. The median stay is 2 days. We only included patients with an expected PICU-stay of &gt; 2 days. Therefore, we expected 45/100 patients with a PICU-stay &gt; 5 days. 
</statisticalmethods>
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs>Natural history</purposeobs>
    <duration>Cross-sectional</duration>
    <selection>Defined population</selection>
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate />
    <actualstartdate>4/04/2014</actualstartdate>
    <anticipatedenddate />
    <actualenddate>8/04/2015</actualenddate>
    <samplesize>160</samplesize>
    <actualsamplesize>160</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate>15/04/2015</anticipatedlastvisitdate>
    <actuallastvisitdate>5/05/2015</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Karolinska University Hospital</primarysponsorname>
    <primarysponsoraddress>FoUU-enheten 
Karolinska Universitetssjukhuset/Karolinska University Hopsital
17176 Stockholm
Sweden

</primarysponsoraddress>
    <primarysponsorcountry>Sweden</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>Karolinska University Hospital</fundingname>
      <fundingaddress>FoUU-enheten 
Karolinska Universitetssjukhuset/Karolinska University Hospital
17176 Stockholm
Sweden
</fundingaddress>
      <fundingcountry>Sweden</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Prof Jan Wernerman</othercollaboratorname>
      <othercollaboratoraddress>AnOpIVA Clinic
Plan 3 K32/B32
Karolinska University Hospital 
141 86 Stockholm
Sweden</othercollaboratoraddress>
      <othercollaboratorcountry>Sweden</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Prof Olav Rooyackers</othercollaboratorname>
      <othercollaboratoraddress>Dept of Clinical Science, Intervention and Technology (CLINTEC), H9
Dept Anesthesia
Karolinska University Hospital, K32
141 86 Stockholm
Sweden </othercollaboratoraddress>
      <othercollaboratorcountry>Sweden</othercollaboratorcountry>
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Reduced serum selenium concentration is common in adult critically ill patients and correlates to increased morbidity and mortality. Parallel supplementation has in a few studies shown reduced mortality rate and less infectious complications. Pediatric critically ill have not been studied and normal values for Scandinavian pediatric population is not known. Selenium supplementation in premature neonatal have shown less infectious complications. In this study we aim to characterize the normal serum concentration of selenium in healthy children to be commenced for elective surgery (n=60). In parallel pediatric critically ill including newborns (n=100) will be characterized concerning selenium- and glutathione status. This approach might reveal anti-oxidative capacity and mechanisms. Secondary aims are to investigate if the selenium- and glutathione profiles correlate to length of stay and severity of illness (PELOD, PIM2).</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>The Regional Ethical Review Board in Stockholm</ethicname>
      <ethicaddress>Nobels vag 9,D3
171 65 Solna
</ethicaddress>
      <ethicapprovaldate>4/02/2014</ethicapprovaldate>
      <hrec>EPN 2013/2110-31/3</hrec>
      <ethicsubmitdate />
      <ethiccountry>Sweden</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Urban Flaring</name>
      <address>Department of Pediatric Anaesthesia and Intensive Care
Astrid Lindgrens Childrens' Hospital
Karolinska University Hospital 
17176 Stockholm
Sweden
</address>
      <phone>+46 8 51770394</phone>
      <fax />
      <email>urban.flaring@karolinska.se</email>
      <country>Sweden</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Urban Flaring</name>
      <address>Department of Pediatric Anaesthesia and Intensive Care 
Astrid Lindgrens Childrens' Hospital
Karolinska University Hospital 
17176 Stockholm
Sweden
</address>
      <phone>+46 8 51770394</phone>
      <fax />
      <email>urban.flaring@karolinska.se</email>
      <country>Sweden</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Urban Flaring</name>
      <address>Department of Pediatric Anaesthesia and Intensive Care
Astrid Lindgrens Childrens' Hospital
Karolinska University Hospital 
17176 Stockholm
Sweden
</address>
      <phone>+46 8 51770394</phone>
      <fax />
      <email>urban.flaring@karolinska.se</email>
      <country>Sweden</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>L Mikael Broman</name>
      <address>ECMO Centre Karolinska
Karolinska University Hospital 
17176 Stockholm
Sweden
</address>
      <phone>+46 8 51778066</phone>
      <fax>+46 8 51778060</fax>
      <email>lars.broman@karolinska.se</email>
      <country>Sweden</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>